Role of angiotensin - converting enzyme inhibitors in <font color="red">early_1</font> <font color="red">antihypertensive_1</font> <font color="red">treatment_1</font> <font color="red">in_1</font> <font color="red">non_2</font> <font color="red">-_2</font> <font color="red">insulin_2</font> <font color="red">dependent_2</font> <font color="red">diabetes_2</font> <font color="red">mellitus_2</font> <font color="red">._2</font> 
<br>
<br> The effect of captopril monotherapy on blood pressure and metabolism was investigated in a placebo - controlled study in <font color="red">30_5</font> <font color="red">non_6</font> <font color="red">-_6</font> <font color="red">insulin_6</font> <font color="red">dependent_6</font> <font color="red">(_6</font> <font color="red">Type_6</font> <font color="red">II_6</font> <font color="red">)_6</font> <font color="red">diabetic_6</font> <font color="red">subjects_5</font> <font color="red">during_3</font> <font color="red">a_3</font> <font color="red">3-week_3</font> <font color="red">observation_3</font> <font color="red">period_3</font> <font color="red">(_2</font> <font color="red">run_2</font> <font color="red">-_2</font> <font color="red">in_2</font> <font color="red">/_2</font> <font color="red">drug_2</font> <font color="red">;_2</font> <font color="red">placebo_2</font> <font color="red">/_2</font> <font color="red">wash_2</font> <font color="red">-_2</font> <font color="red">out_2</font> <font color="red">)_2</font> <font color="red">on_2</font> <font color="red">a_2</font> <font color="red">metabolic_2</font> <font color="red">ward_2</font> <font color="red">._2</font> Captopril significantly reduced both systolic and diastolic blood pressure ( 154/90 + /- 5/2 vs. 144/86 + /- 4/3 mmHg ) without major side effects . Mean run - in postprandial blood glucose concentrations were also reduced upon ACE - inhibition ( 9 a.m. : 12.7 + /- 0.4 vs. 11.1 + /- 0.4 mmol / l ; 1 p.m. : 11.0 + /- 0.3 vs. 8.9 + /- 0.3 mmol / l ; P less than 0.05 ) , while blood kinin concentrations ( 40.0 + /- 2.5 pmol / l ) were approximately doubled ( 108.8 + /- 23.5 pmol / l ; P less than 0.05 ) . Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile as well as hepatic and renal function parameters remained unaltered throughout the observation period . The data are in line with recent experimental studies showing a beneficial metabolic effect of captopril in <font color="red">Type_1</font> <font color="red">II_1</font> <font color="red">diabetes_1</font> <font color="red">._1</font> ACE inhibitors might therefore become first - line drugs in early antihypertensive intervention in <font color="red">Type_2</font> <font color="red">II_2</font> <font color="red">diabetic_2</font> <font color="red">patients_1</font> <font color="red">._1</font>